Nov. 5, 2015 | Cathy Starner
Engaging Medicare members improves adherence, can lead to higher Star ratings
To learn how MTM programs impact adherence — and eventually Star ratings — our team of researchers analyzed pharmacy claims data for 1.2 million Medicare members. We compared adherence between qualified members who engaged in MTM* vs. those who did not within the three drug adherence Star ratings categories: diabetes, statins and renin angiotensin system (RAS) antagonists.
Oct. 15, 2015 | Prime Therapeutics
How do cost and pharmacy choice impact adherence to hepatitis C blockbusters?
Can out-of-pocket costs and pharmacy choice for blockbuster hepatitis C medicines significantly impact adherence and abandonment rates? Prime’s clinical researchers analyzed out-of-pockets costs, abandonment and compliance rates for members who initiated at least one Sovaldi fill at Prime Therapeutics Specialty PharmacyTM and those who used other specialty pharmacies.
Feb. 3, 2014 | Prime Therapeutics
Study finds lower cost of care and improved adherence with Prime Specialty Pharmacy
Generally, members who stick to their specialty drug regimens are likely to have lower cost of care due to fewer complications and doctor visits. Prime strives to keep members adherent through an effective and efficient care management program, offering services beyond what they would receive in a standard pharmacy. In a separate study, specialty drug adherence was found to be higher among members using Prime Specialty Pharmacy compared to a standard retail pharmacy.
April 4, 2014 | Patrick Gleason
What does $250 buy? More appropriate drug use
Nearly one third of all initial drug prescriptions were not filled within nine months. Nonadherence was highest for expensive drugs and chronic preventive therapies. Prime’s clinical outcomes team studied this problem in two specialty drug categories: multiple sclerosis (MS) and biologic anti-inflammatory (BAI) drugs used to treat conditions like rheumatoid arthritis, psoriasis and Crohn’s disease. We found that members who paid less than $250 out-of-pocket were much more likely to start MS or BAI therapy.
March 28, 2014 | Prime Therapeutics
Presenting new pharmacy insights
Prime’s clinical research team will present findings from four studies:
- Out-of-pocket costs and specialty prescription abandonment
- Using member characteristics and costs to identify potential high-risk opioid use
- Results of pharmacist consultation aimed at preventing opioid overutilization
- Specialty drug adherence at Prime Specialty Pharmacy versus retail pharmacy